Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
- 1 December 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (12), 1884-1896
- https://doi.org/10.1016/j.jtho.2018.09.012
Abstract
No abstract availableKeywords
Funding Information
- NIH
- Yale SPORE in Lung Cancer (P50-CA196530)
- Stand Up To Cancer
This publication has 57 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJCI Insight, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancerOncogene, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Direct observation of individual endogenous protein complexes in situ by proximity ligationNature Methods, 2006
- Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and PrognosisJNCI Journal of the National Cancer Institute, 2005
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005